olivLaw · US equity research
argenx SE ARGX
Biological Products, (No Diagnostic Substances) · SIC 2836 · Vertical: Biological Products, (No Diagnostic Substances) (SIC 2836)
argenx SE is an Amsterdam-based biotechnology company that develops and sells VYVGART, an efgartigimod treatment for rare autoimmune diseases. Product net sales reached $4.2 billion in fiscal 2025, and the company reported its second consecutive year of profitability, making the evolution of its pipeline relevant now.
The AI analysis may be outdated: new filings came after its sources (see the «AI analysis» section).
At the close of 04 Nov 2026, argenx SE (ARGX) stock was 931.38 USD (+3.36% on the day), with market capitalisation 57.6 bn USD, P/E 47.6 on diluted EPS of 19.57 USD over the last 12 months, beta 0.44, 52-week range 663.93–1,058.90 USD.
Data as of · AI analysis dated · Source: SEC filings and closing prices, computed by olivLaw.
Price history
Loading chart…
Technical reading
- RSI (14)
- 58.6
- strong (55–70)
- Bollinger (20, 2)
- 789.09 – 932.81
- in the upper half of the band · %B 0.99 · band width 16.7%
- SMA 50 / 200
- 936.35 / 856.15
- mixed trend
- MACD (12, 26, 9)
- -3.65 / -14.16
- MACD above signal
Indicators describe past prices; on their own they do not predict direction. On our history the RSI ≤ 40 filter added no return (see the signals methodology).
Performance
| Company | S&P 500 | vs S&P 500 | Vertical median | |
|---|---|---|---|---|
| 1 month | +2.0% | −1.1% | +3.1 pp | — |
| 3 months | +7.3% | −0.5% | +7.8 pp | — |
| 6 months | +15.3% | +4.4% | +10.9 pp | — |
| Year to date | +10.8% | +12.3% | −1.6 pp | — |
| 1 year | +12.0% | +13.5% | −1.5 pp | −3.8% |
| 3 years | +86.3% | +76.4% | +9.9 pp | +18.6% |
| 5 years | +190.2% | +63.7% | +126.5 pp | — |
Price returns, dividends excluded.
Quarterly results
ESEF annual reports carry no quarters: the results are annual (below).
E/P over time
E/P = trailing-12-month diluted EPS / price at quarter end. E/P is the inverse of P/E and stays defined when earnings are negative.
Today's P/E sits at the 50 percentile of its own 2-quarter history (min 43.0, median 45.5, max 48.1; quarters with earnings only).
Fiscal years
| Fiscal year | 2018 | ⚠ 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21.5 m | 78.5 m | 41.2 m | 497.3 m | 10.0 m | 35.5 m | unavailable | unavailable |
| Revenue YoY | −41.0% | — | −47.4% | +1,105.7% | −98.0% | +254.4% | unavailable | unavailable |
| Net income | -66.6 m | -163.0 m | -608.5 m | -408.3 m | -709.6 m | -295.1 m | 833.0 m | 1.3 bn |
| Net income YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | unavailable | +55.1% |
| Diluted EPS | unavailable | -4.69 | -13.40 | -7.99 | -13.05 | -5.16 | 12.78 | 19.57 |
| Diluted EPS YoY | unavailable | — | unavailable | unavailable | unavailable | unavailable | unavailable | +53.1% |
| net % | -310.2% | -207.7% | -1,475.3% | -82.1% | -7,077.5% | -830.4% | unavailable | unavailable |
| Free cash flow | unavailable | 149.8 m | -399.5 m | -610.4 m | -863.6 m | -421.1 m | -84.5 m | 679.0 m |
The series breaks before 2019: earlier years come from the original reports of the issuer of that time, later years from a subsequent filing that restated the perimeter (a separation, discontinued operations). The year-on-year change across the break is not shown.
Reported results vs expectations
Loading…
Balance sheet & financial health
Fiscal year 2025 · 31 Dec 2025
- Cash
- 3.5 bn USD
- Financial debt
- unavailable USD
- Net debt
- unavailable USD
- Equity
- 7.3 bn USD
- Total assets
- 8.7 bn USD
- Debt / equity
- unavailable
- Current ratio
- 5.23x
- ROE
- 20.2%
- ROA
- 17.4%
- FCF margin
- unavailable
Financial statements (source on every figure)
Revenue and net income (USD)
Margins
Income statement · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Revenue | 41.2 m | 497.3 m | 10.0 m | 35.5 m | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Cost of revenue | — | — | 29.4 m | 117.8 m | 227.3 m | 450.7 m | SEC (XBRL)· 19 Mar 2026verified |
| Gross profit | — | — | -19.4 m ≈ | -82.3 m ≈ | — | — | SEC (XBRL)· 21 Mar 2024derived |
| Research & development | 370.9 m | 580.5 m | 663.4 m | 859.5 m | 983.4 m | 1.4 bn | SEC (XBRL)· 19 Mar 2026verified |
| Operating income | -477.6 m | -348.7 m | -720.3 m | -425.0 m | -21.7 m | 1.1 bn | SEC (XBRL)· 19 Mar 2026verified |
| Interest expense | 8.0 m | 4.6 m | 3.9 m | 906.0 k | 2.5 m | 4.1 m | SEC (XBRL)· 19 Mar 2026verified |
| Pre-tax income | -605.4 m | -399.7 m | -729.3 m | -304.5 m | 85.2 m | 1.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Income tax | 3.1 m | 8.5 m | -19.7 m | -9.4 m | -747.9 m | -13.4 m | SEC (XBRL)· 19 Mar 2026verified |
| Net income | -608.5 m | -408.3 m | -709.6 m | -295.1 m | 833.0 m | 1.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Diluted EPS | -13.40 | -7.99 | -13.05 | -5.16 | 12.78 | 19.57 | SEC (XBRL)· 19 Mar 2026verified |
| Weighted average diluted shares | — | — | 54.4 m | 57.2 m | 65.2 m | 66.0 m | SEC (XBRL)· 19 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Revenue − Cost of revenue.
Balance sheet · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Cash | 1.2 bn | 1.3 bn | 800.7 m | 2.0 bn | 1.5 bn | 3.5 bn | SEC (XBRL)· 19 Mar 2026verified |
| Receivables | 7.0 m | 38.2 m | 275.7 m | 496.7 m | 904.5 m | 1.6 bn | SEC (XBRL)· 19 Mar 2026verified |
| Inventories | 25.2 m | 109.1 m | 228.4 m | 310.6 m | 407.2 m | 473.5 m | SEC (XBRL)· 19 Mar 2026verified |
| Current assets | 2.1 bn | 2.5 bn | 2.8 bn | 4.1 bn | 4.9 bn | 6.9 bn | SEC (XBRL)· 19 Mar 2026verified |
| Property, plant & equipment, net | 11.6 m | 15.8 m | 16.2 m | 22.7 m | — | — | SEC (XBRL)· 21 Mar 2024verified |
| Intangibles (excl. goodwill) | 167.3 m | 171.7 m | 174.9 m | 125.2 m | 181.4 m | 272.1 m | SEC (XBRL)· 19 Mar 2026verified |
| Total assets | 2.3 bn | 2.9 bn | 3.1 bn | 4.5 bn | 6.2 bn | 8.7 bn | SEC (XBRL)· 19 Mar 2026verified |
| Accounts payable | 275.2 m | 293.4 m | 295.7 m | 414.0 m | 650.0 m | 1.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Current liabilities | 328.5 m | 301.2 m | 302.3 m | 423.0 m | 669.9 m | 1.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Total liabilities | 605.4 m | 316.1 m | 320.6 m | 445.0 m | 704.2 m | 1.4 bn | SEC (XBRL)· 19 Mar 2026verified |
| Equity | 1.7 bn | 2.5 bn | 2.8 bn | 4.1 bn | 5.5 bn | 7.3 bn | SEC (XBRL)· 19 Mar 2026verified |
| Shares outstanding at year end | 47.6 m | 51.7 m | 55.4 m | 59.2 m | 60.8 m | 61.9 m | SEC (XBRL)· 19 Mar 2026verified |
Cash flow · USD
| Line | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Source (latest year) |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -398.5 m | -606.8 m | -862.8 m | -420.3 m | -82.7 m | 685.2 m | SEC (XBRL)· 19 Mar 2026verified |
| Capex | 1.1 m | 3.6 m | 837.0 k | 812.0 k | 1.8 m | 6.2 m | SEC (XBRL)· 19 Mar 2026verified |
| Free cash flow | -399.5 m ≈ | -610.4 m ≈ | -863.6 m ≈ | -421.1 m ≈ | -84.5 m ≈ | 679.0 m ≈ | SEC (XBRL)· 19 Mar 2026derived |
| Investing cash flow | 344.7 m | -347.1 m | -461.2 m | 308.2 m | -717.6 m | 984.0 m | SEC (XBRL)· 19 Mar 2026verified |
| Financing cash flow | 833.0 m | 1.1 bn | 843.8 m | 1.3 bn | 279.8 m | 233.0 m | SEC (XBRL)· 19 Mar 2026verified |
≈ computed by olivLaw from the reported lines of the same year: Operating cash flow − Capex.
Computed indicators
Growth
Profitability
Returns
Balance sheet
Liquidity
Cash
Efficiency
Market and valuation
1 indicators that do not apply to the sector.
Valuation
olivLaw classification
- score weight coverage: 43.8% of at least 60%
A scoring methodology on indicators and valuation, not investment advice.
Closing price
04 Nov 2026Source: olivLaw, closing series
Market cap: 57.6 bn USD
Key indicators
Coverage and freshness
Score by group
44% · Insufficient data
Estimated value range
The combined range = the median of the valid methods' low, central and high values; it is not a probability interval and does not cover every result. Envelope of all methods: 425.64 – 751.96 USD.
Valuation assumptions are editorial choices, not measured; beta is not measured.
Method ranges (USD per share)
— — Mid · ▏ Price
Valuation methods
- DCF (discounted cash flow)unavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: EV/EBITDAunavailable · net debt missing: EV cannot be bridged to equity (missing debt is not zero)
- Peers: P/E425.64 – 751.96 (Mid 542.85)5 companies used · median multiple 27.7x · quartiles 21.7x – 38.4xADMA, ALVO, AMGN, EXEL, HALO
- Dividend discount (DDM)unavailable · the company pays no dividend: a dividend model needs an explicit initiation assumption
Classification (SIC) comparables group by industry code, not by economic activity; the direct group is an editorial selection by activity. Members' multiples are on their own trailing twelve months, at their own latest close.
Assumptions (illustrative, editorial)
- Risk-free rate
- 4.3%
- Equity risk premium
- 5.0%
- Beta (default)
- 1.00
- Cost of equity
- 9.3%
- Terminal growth
- 2.5%
Factor scorecard
Insufficient data
Minimum-evidence gate: score weight coverage: 43.8% of at least 60%
| Factor | Value | Score | Weight used |
|---|---|---|---|
| ROIC · Quality | unavailable | unavailable | — |
| Net margin · Quality | unavailable | unavailable | — |
| FCF conversion · Quality | 52.6% | 32 (on a fixed band) | 14% |
| Revenue CAGR 3Y · Growth | -4.8% | 0 (on a fixed band) | 19% |
| EPS CAGR 3Y · Growth | unavailable | unavailable | — |
| Net debt / EBITDA · Balance sheet | unavailable | unavailable | — |
| Interest coverage · Balance sheet | 258.2x | 100 (on a fixed band) | 14% |
| Current ratio · Balance sheet | 5.2x | 100 (on a fixed band) | 10% |
| P/E (TTM) · Valuation | 47.6x | 29 (vs peers) | 24% |
| EV/EBITDA · Valuation | unavailable | unavailable | — |
| FCF yield · Valuation | 1.2% | 15 (on a fixed band) | 19% |
| Shareholder yield (distributions) · Returns | unavailable | unavailable | — |
| Payout ratio (FCF) · Returns | unavailable | unavailable | — |
Factors without a value were dropped; the remaining weights were renormalised.
Score groups
- Balance sheet100/100 · 2/3 factors with a value
- Growth· partial0/100 · 1/2 factors with a value
- Quality· partial32/100 · 1/3 factors with a value
- Returns· partialunavailable · 0/2 factors with a value
- Valuation22/100 · 2/3 factors with a value
A «partial» group is computed from under half of its weight or from one factor: it is not a full assessment of the group.
Memo
ARGENX SE (ARGX). Latest full fiscal year: 2023; data up to 2025-12-31.
Figures computed from the financial statements: revenue 35.5 m USD in 2023; YoY growth 254.4%; ROE 20.2%.
The estimated value range is 425.64–751.96 USD per share (median of 1 methods, agreement: single method); assumptions are illustrative. Against the central value of 542.85 USD, the price of 931.38 USD leaves a potential of -41.7% (value / price − 1) and a margin of safety of -71.6% (1 − price / value). The range is the median of the methods' low, central and high values, not a probability interval.
Insufficient data for a verdict (score weight coverage: 43.8% of at least 60%).
Text generated deterministically from the figures shown; no language model. Not investment advice.
What supports the thesis
- Interest coverage: 258.2x
- Current ratio: 5.2x
What contradicts it
- Revenue CAGR 3Y: -4.8%
- P/E (TTM): 47.6x
- FCF yield: 1.2%
- The price is above the estimated value range
Not assessed (insufficient data or a ratio without meaning): ROIC, Net margin, EPS CAGR 3Y, Net debt / EBITDA, EV/EBITDA, Shareholder yield (distributions), Payout ratio (FCF).
Versus the vertical median
Biological Products, (No Diagnostic Substances) (SIC 2836) · same industry (4-digit SIC) · compared with 39 companies
Multiples and returns vs the median
Price rebased to 100 (monthly, 5 years)
Companies in the vertical
| Market cap | P/E | ROE | Net margin | Revenue YoY | 1A / 3A | |
|---|---|---|---|---|---|---|
| AMGNAmgen Inc. | 258.8 bn | 27.7 | 78.4% | 24.1% | +10.0% | +39% / +77% |
| GILDGilead Sciences, Inc. | 216.4 bn | — | -22.3% | -12.5% | +2.4% | +39% / +128% |
| MRNAModerna, Inc. | 103.2 bn | — | -39.0% | -141.4% | −39.9% | +895% / +233% |
| ARGXArgenx Se | 57.6 bn | 47.6 | 20.2% | — | +254.4% | +12% / +86% |
| RVMDRevolution Medicines, Inc. | 43.2 bn | — | -93.6% | -946.8% | unavailable | +157% / +756% |
| BIIBBiogen Inc. | 37.6 bn | 108.8 | 1.9% | 3.4% | +2.2% | +40% / +9% |
| MESOMesoblast Limited | 18.5 bn | — | -19.0% | -593.9% | +191.4% | −17% / +425% |
| EXELExelixis, Inc. | 17.8 bn | 21.7 | 44.3% | 35.5% | +7.0% | +65% / +234% |
| HALOHalozyme Therapeutics, Inc. | 14.8 bn | 38.4 | 173.7% | 24.9% | +37.6% | +83% / +238% |
| KYMRKymera Therapeutics, Inc. | 11.6 bn | — | -27.3% | -341.8% | −16.7% | +101% / +556% |
| TWSTTwist Bioscience Corporation | 8.9 bn | — | -29.6% | -31.7% | +20.3% | +345% / +493% |
| SCNIScinai Immunotherapeutics Ltd. | 6.2 bn | — | -91.9% | -633.6% | +99.2% | −96% / −99% |
| CGONCG Oncology, Inc. | 6.0 bn | — | -26.4% | -3,602.7% | +254.7% | +51% / unavailable |
| TARSTarsus Pharmaceuticals, Inc. | 3.4 bn | — | -319.8% | -102.9% | +146.7% | −14% / +318% |
| DNLIDenali Therapeutics Inc. | 3.4 bn | — | -33.9% | -1,470.5% | unavailable | +8% / +13% |
| VCELVericel Corporation | 2.3 bn | 107.7 | 7.2% | 7.9% | +16.5% | +13% / +28% |
| ADMAAdma Biologics, Inc. | 2.3 bn | 13.6 | 41.9% | 35.1% | +19.6% | −45% / +183% |
| BCRXBiocryst Pharmaceuticals, Inc. | 2.1 bn | — | — | -37.4% | +94.1% | +15% / +40% |
| VIRVir Biotechnology, Inc. | 2.0 bn | — | -21.8% | -61.0% | −7.6% | +83% / +24% |
| ALVOAlvotech | 1.5 bn | 46.7 | — | 4.8% | +19.7% | −8% / −51% |
| INBXInhibrx Biosciences, Inc. | 1.3 bn | — | -1,773.6% | — | +550.0% | +3% / unavailable |
| EVAXEvaxion A | 1.2 bn | — | -100.2% | -102.4% | +125.1% | −50% / −93% |
| CADLCandel Therapeutics, Inc. | 692.5 m | — | -81.8% | — | 0.0% | +90% / +907% |
| SRZNSurrozen, Inc. | 372.0 m | — | — | -2,885.3% | −67.4% | +91% / +340% |
| AUTLAutolus Therapeutics plc | 367.3 m | — | -133.0% | -238.7% | +644.9% | −2% / −68% |
1- and 3-year price returns: for ARGX from daily closes (the same as the performance table), for the other companies from month-end closes.
olivLaw engine forecast
The world engine ran after the company's latest material disclosure. Probabilities are of TOUCHING a level within the horizon (not closing there) and sit next to the random walk (p_rw), the no-information benchmark.
The engine has no published run for this company yet.
Valuation scenarios (editable assumptions)
Illustrative scenarios
Scenarios are not available. input data missing
AI analysis
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 19 Mar 2026; since then the company filed 6-K (22 Oct 2026), 6-K (19 Oct 2026), 6-K (08 Oct 2026), 6-K (29 Sept 2026), 6-K (27 Aug 2026), 6-K (17 Aug 2026).
In brief
argenx SE is an Amsterdam-based biotechnology company that develops and sells VYVGART, an efgartigimod treatment for rare autoimmune diseases. Product net sales reached $4.2 billion in fiscal 2025 1, and the company reported its second consecutive year of profitability, making the evolution of its pipeline relevant now.
SWOT
Strengths
- Rapid sales growth and early operating profitability, supported by a product already on the market.
- Proprietary antibody discovery platform and an innovation program that generates new candidates.
- Solid balance sheet providing flexibility to invest in research and global expansion.
Weaknesses
- Heavy dependence on one main product, VYVGART, for most revenue.
- Rising research and sales costs that could slow progress toward steady profitability.
- A history of accumulated losses that has not yet been fully eliminated.
Opportunities
- Indication expansion for seronegative and other autoimmune diseases could open new patient segments.
- Launches in new markets and more convenient formulations could increase access to treatment.
- Pipeline results, including Phase 3 studies, could strengthen the company's long-term position.
Threats
- Biosimilars or competing products could reduce market share and prices.
- Pricing reforms and regulations in the US and EU could limit revenue.
- Competitors using artificial intelligence or new technologies could advance more quickly.
Risks
- Market acceptancehigh
Products could fail to achieve sufficient acceptance by physicians and payers to sustain profit.
- Competitive launcheshigh
Competitive launches could erode existing sales or lead to product obsolescence.
- Biosimilarsmedium
Regulatory exclusivity could be shortened through legislative action, allowing biosimilars to enter sooner.
- Pricing legislationmedium
US drug price negotiation programmes could reduce prices and change patient access to products.
- Clinical developmentmedium
Negative clinical results for one indication could affect perceptions of other indications.
Investment thesis
What would need to be true (bull case)
- Rapid growth in VYVGART sales and the first year of operating profitability could support continued development.
- Results from several Phase 3 studies scheduled for 2026 and 2027 could significantly expand the pipeline.
- The proprietary discovery platform and partnerships could keep generating new molecules.
What would break the thesis
- Dependence on a single product could leave revenue exposed to competitive or pricing pressure.
- Rising research and sales expenses could compress margins if sales slow.
- Biosimilars or new therapies could erode market position before protection expires.
What to watch
- Results of the seronegative myasthenia gravis study and the FDA decision2026
- Results of the empasiprubart MMN study and the efgartigimod primary ITP studyQ4 2026
- Effects of pricing reforms and biosimilar legislation2027
Products, market & competition
AI-generatedAI-generated analysis (Claude) from cited public sources; it may contain errors. Not investment advice. As of 27 Oct 2026 · Model: claude-haiku-5-5.
Possibly outdated: the newest document it read is from 19 Mar 2026; since then the company filed 6-K (22 Oct 2026), 6-K (19 Oct 2026), 6-K (08 Oct 2026), 6-K (29 Sept 2026), 6-K (27 Aug 2026), 6-K (17 Aug 2026).
The business
argenx SE is a Netherlands company incorporated in 2008 whose research and development has been carried out since 2009 through its subsidiary argenx BV 1. The company focuses on biologic medicines for autoimmune diseases, with VYVGART as its lead product, approved for several indications including gMG and CIDP 1. Its strategy relies on its antibody discovery platform and an immunology innovation program feeding the pipeline. The Vision 2030 plan targets five molecules in Phase 3, ten labeled indications and 50,000 patients treated 1.
Segments
VYVGART and its formulations
VYVGART is approved in three active indications and three presentations (IV, SC and prefilled syringe), and is commercialized through its own sales forces in the US, Japan, Europe and Canada 1. Sales grew from $2.2 billion in 2024 to $4.2 billion in 2025 1.
Proprietary pipeline
The pipeline includes empasiprubart, a C2 complement inhibitor in three Phase 3 studies, and adimanebart, in Phase 3 for CMS 1. Several new molecules are planned to enter Phase 1 in 2026 1.
Partnerships and licences
The company out-licensed efgartigimod in Greater China to Zai Lab and out-licensed several candidates from its immunology program to partners under milestone and royalty agreements 1. These generate additional income contingent on sales.
Market context
Trends
- Indication expansiontailwind
Ongoing studies in seronegative myasthenia gravis and other autoimmune diseases could widen the addressable market if results are favorable 1.
- Biosimilar competitionheadwind
If biosimilars or interchangeable products were approved before exclusivity expires, prices and market share could be affected 1.
- US pricing pressureheadwind
The IRA could reduce prices and increase rebate obligations, affecting demand, although the programme remains subject to legal challenges 1.
- Artificial intelligence in discoverymixed
Competitors using artificial intelligence could advance faster, which could create competitive pressure on the pipeline 1.
Competitive position
The source cites intense competition from large pharmaceutical companies and other biotechs developing therapies for gMG, CIDP and other autoimmune diseases 1. This includes both products in the same class as VYVGART and new alternatives 1.
Competition for future indications is equally fierce, with competitors developing in almost all indications the company is pursuing 1.
- AstraZenecaAZN
Large pharmaceutical company listed on several exchanges, named in the source as developing autoimmune therapies.
- AbbVieABBV
Major pharmaceutical company with autoimmune products and studies, explicitly named in the source.
- AmgenAMGN
Biotechnology company with biologics in development for autoimmune disorders, cited in the competition risks.
- Johnson & JohnsonJNJ
Pharmaceutical group named as one of the competitors in immunology.
Links, dependencies and risks
Who the company is tied to, from its own SEC filings (customers, suppliers, production, partners, competitors, countries, regulation), from the 5 %+ holders' statements (13D/13G) and from what other companies say about it. Click a node for its evidence; on a listed company the graph moves to it.
Loading the links…
News & filings
In the press
No news in our archive over the last 180 days.
SEC filings
- Current report (foreign issuer)22 Oct 2026
- Current report (foreign issuer)19 Oct 2026
- Current report (foreign issuer)08 Oct 2026
- Current report (foreign issuer)29 Sept 2026
- Current report (foreign issuer)27 Aug 2026
- Current report (foreign issuer)17 Aug 2026
- Current report (foreign issuer)03 Aug 2026
- Current report (foreign issuer)27 Jul 2026
- Current report (foreign issuer)23 Jul 2026
- Current report (foreign issuer)23 Jun 2026
Sources
- [1] Form 20-F, fiscal year ended 2025-12-31 · SEC / argenx SE · 19 Mar 2026
Figures computed by olivLaw from SEC filings and closing prices; the qualitative analysis is AI-generated from cited sources. Not investment advice.